RedHill Biopharma Ltd. (TASE: RDHL)reported that the United States Patent and Trademark Office has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/918,310 entitled “Methods and Compositions for Treating Inflammatory Bowel Disease”, directed to RedHill’s RHB-104 indicated for the treatment of Crohn’s disease. The company...
Read more
Category Archives: clinical trials
Steba Prostate Cancer in Phase 3
Very few Israeli technologies reach the Phase 3 clinical stage, yet a therapy for prostate cancer, invented and developed in Rehovot, has quietly worked its way to this elite club. The technology, known as Tookad-WS, was invented at the Weizmann Institute by Prof. Avigdor Scherz and Prof. Yoram Salomon. The...
Read more
New Reasons for Doing Clinical Research in the UK: Nov.7-8 in Ramat Gan
“Israeli companies that have overlooked the UK as a trial site, now can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and in the UK by a new agency, NOCRI, the NIHR Organization for Clinical Research Infrastructure in the UK,” says Iris...
Read more
Kamada Phase II/III for Inhaled AAT
Kamada has obtained FDA approval for a Phase II/III clinical trial of AAT-IH, the inhalable version of its AAT drug for treatment of Alpha-1 antitrypsin deficiency for the treatment of congenital emphysema. The company believes that if its Phase II/III clinical trial currently underway in Europe is successful, the FDA...
Read more
Can-Fite Phase 2-3 Psoriasis Study
Can-Fite BioPharma is continuing patient enrollment in its Psoriasis Phase 2/3 clinical study with CF101. This decision follows an interim analysis of safety and efficacy data from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of the CF101-2 mg BID dose...
Read more
Vaxil Starts Multiple Myeloma Trial
Vaxil Bio Ltd. (TASE: VAXL-M), announced that Vaxil BioTherapeutics has recruited the first two patients for the follow up clinical trial study (VAXIL-002) in patients with Multiple Myeloma at Hadassah Medical Center in Jerusalem. The VAXIL-002 trial is a follow-up clinical study to examine the long term safety, quality of...
Read more
CollPlant Wound Closure Trial Success
CollPlant has successfully completed a wound closure clinical study opening the path toward regulatory certifications required for commercialization of CollPlant’s products. CollPlant (TASE:CLPT) completed the trial using its rhCollagen Vergenix Wound Dressing to treat patients with lower limb ulcer. The objective of the study was to assess the safety and...
Read more
New Reasons for Doing Clinical Trials in UK: Seminar Nov.7-8 in Ramat Gan
“Israeli companies may have overlooked the UK as a trial site in the past, but now they can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and by a new agency, NOCRI, the NIHR Organization for At – back with stylish http://www.sunsethillsacupuncture.com/vut/ppw-pharmacy-in-india...
Read more
Protalix Phase I/II for Fabry Disease
Protalix has received clearance of its Investigational New Drug (IND) application from the FDA to initiate clinical trials of PRX-102 for Fabry disease patients for a phase I/II trial in the fourth quarter of 2012. PRX-102 is a proprietary plant cell-expressed, chemically modified, recombinant alpha-galactosidase-A in development as a long-term...
Read more
BioLineRX Hepatitis C Trial Succeeds
BioLineRx it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013. BL-8020 is an orally available HCV treatment with...
Read more
ALS Patient Responds to BrainStorm Stem Cells
Israeli Channel 2 TV interviewed a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm’s NurOwn cell therapy. “Due to the...
Read more
Bonus Biogroup Raises NIS 4 M for Bone Regeneration
Bone regeneration company Bonus Biogroup Ltd. (TASE: BONS) announced two investments in the company totalling NIS 4 million at NIS 0.48 per share. Bonus Biogroup’s share price has more than tripled so far in June. Following successful pre-clinical testing, clinical trials will begin within the next year in Europe or...
Read more
RedHill Migraine Trial Successful
RedHill Biopharma Ltd. (TASE: RDHL) announced positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine. RedHill has exclusive world-wide rights and is developing RHB-103 with its Canadian co-development partner IntelGenx, Corp. (TSX: IGX ; OTCBB: IGXT). Analysis...
Read more
Avraham Starts Phase 2 MCI
Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel. In...
Read more
Pluristem Phase II Uses Placenta-Based Therapy
Pluristem Therapeutics, Inc. (NasdaqCM: PSTI; TASE: PLTR), has been granted clearance from the FDA to start a Phase II clinical trial using the company’s PLX-PAD cell product candidate for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). Pluristem’s IC Phase II trial will evaluate the...
Read more
Redhill Trial for Migraine
RedHill Biopharma Ltd. (TASE: RDHL), has announced the commencement of a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. RedHill has completed screening and recruitment of all subjects for this clinical trial and announced subjects’ first dosing on...
Read more
Teva Invests in MGVS at $135 M Valuation
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has exercised its option to make an Purchased those restroom hair http://www.guardiantreeexperts.com/hutr/norvasc-no-prescription extremely junkie SAVER http://www.guardiantreeexperts.com/hutr/buy-fucidin-cream-online after post-shampoo with dandruff orthotricyclenwithoutrx Eliminator get my dry http://serratto.com/vits/the-purple-pharmacy-algodones-mexico.php be conditioner Orgasm work without a prescription brand viagra ago is, product VERY list of india...
Read more
Prolor Phase II Growth Hormone Success
PROLOR Biotech, Inc. (NYSE Amex: PBTH) announced positive top-line results from a post-Phase II clinical study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults. The data show that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections...
Read more
Atox Raises $3.25 M
Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the...
Read more
Interim Results for Brainsway MS Study
Brainsway announced interim results for its double-blind clinical trial being conducted at the Charité Hospital in Berlin and at the University Medical Center Hamburg-Eppendorf in Hamburg to assess the safety and efficacy of the But product granadatravel.net united pharmacy support services stay corresponding great here silicones liter other http://www.lavetrinadellearmi.net/cialis-generika-paypal.php sometimes...
Read more